Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines

Adil S. Akthar MD, Anthony C. Wong MD, PhD, Akash D. Parekh MD, Greg Hubert BS, RT(T), CMD, Christina H. Son MD, Charles A. Pelizzari PhD, Stanley L. Liauw MD *

Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Illinois

Received 12 October 2017; received in revised form 5 March 2018; accepted 30 April 2018

Abstract

Purpose: Dose-volume histogram (DVH) toxicity relationships are poorly defined in men who receive radiation after radical prostatectomy (RP). We evaluated Radiation Therapy Oncology Group (RTOG) study 0534 and institutional intact normal-tissue sparing guidelines, as well as dose to bladder trigone, for ability to minimize late toxicity.

Methods and materials: 164 men received intensity modulated radiation therapy (RT) to a median prostate bed dose of 66.6 Gy at a median of 22 months after RP. 46% of men were prescribed androgen deprivation therapy and pelvic lymph node irradiation to a median dose of 50.4 Gy. DVH relationships for the rectum, bladder, trigone, and bladder excluding the clinical target volume (bladder-CTV) were analyzed against the Common Terminology Criteria for Adverse Events late grade 2+ (G2+) gastrointestinal (GI) and genitourinary (GU) toxicity by log-rank test. RTOG 0534 (rectum V65, 40 Gy ≤ 35, 55%, and bladder-CTV V65, 40 ≤ 50, 70%) and intact prostate RT institutional guidelines (rectum V70, 65, 40 ≤ 20, 40, 80% and bladder V70, 65, 40 ≤ 30, 60, 80%, respectively) guidelines were evaluated.

Results: With a median follow-up time of of 33 months, the 4-year freedom from G2+ GI and GU toxicity were both 91%. G2 + GI (n = 12) and GU (n = 15) toxicity included 4% diarrhea (n = 6), 4% hemorrhage (n = 6), 1% proctitis (n = 1), and 4% urinary frequency (n = 7), 1% obstructive (n = 2), 2% cystitis (n = 3), and 3% incontinence (n = 5), respectively. RTOG 0534 rectum and bladder goals were not achieved in 65% and 41% of cases, while the institutional intact prostate goals were not achieved in 21% and 25% of cases, respectively. Neither dose to the bladder trigone nor any of the proposed normal tissue goals were associated with late toxicity (P > .1). In the univariate analysis, age, pelvic RT, RT dose, anticoagulation use, androgen deprivation therapy, time from RP to RT, and tobacco history were not associated with toxicity.

Conclusions: More than 90% of men were free from late G2 + toxicity 4 years after post-RP intensity modulated RT. No tested parameters were associated with late toxicity. In the absence of...
Introduction

The minimization of late treatment-related morbidity is highly prioritized in men who receive post-prostatectomy prostate radiation therapy (PPRT) because of their longevity with >74% of patients expected to live at least 10 years after either adjuvant or salvage radiation therapy. Furthermore, most men with prostate cancer will die from competing risks. Despite evidence of improvements in disease control and in some patients survival, adjuvant PPRT remains underutilized, likely due in part to the perceived risk of late toxicity.

These concerns could be mitigated by evidence-based normal-tissue sparing dose constraints for PPRT. However, data that establish dose-volume histogram (DVH) toxicity relationships in the post-prostatectomy setting are sparse. The Radiation Therapy Oncology Group (RTOG) has proposed normal-tissue sparing goals in the protocol for RTOG 0534 (clinicaltrials.gov NCT00567580) but these can be difficult to satisfy because of the large volume of bladder tissue that is included in the prostate bed target volume. Moreover, the clinical consequences of failing to meet RTOG goals have not been assessed and critical organ dose constraints may not be adequately captured by RTOG parameters. Doses to the bladder trigone, for example, are likely underestimated by the RTOG bladder clinical target volume (CTV) parameters due to overlapping CTV and trigone volumes. However, maximum trigone doses have been strongly associated with late genitourinary (GU) toxicity in the intact prostate cancer setting. The absence of data on post-prostatectomy DVH relationships that are associated with late GU and gastrointestinal (GI) toxicity constitutes a critical knowledge gap that prevents radiation oncologists from minimizing the risks of PPRT.

To address this knowledge gap, we reviewed our experience with PPRT and compared our institutional normal tissue-sparing dose constraints to those specified by RTOG 0534. Our primary goal was to assess the ability of both commonly used sets of DVH guidelines to predict late GU and GI toxicity. Our secondary goal was an attempt to improve these guidelines by evaluating the association between dose to the bladder trigone and late GU toxicity.

Methods and materials

Patients

All men who received PPRT between 2001 and 2012 as part of salvage or adjuvant therapy were identified from an internal review board-approved clinical database at a single academic institution. Patient records were prospectively collected.

Treatment

Computed tomography-based simulation and radiation therapy planning were in accordance with recommendations published by the American College of Radiology. All men were treated with intensity modulated radiation therapy (IMRT). Prostate bed volumes were contoured according to anatomy-based interdisciplinary consensus guidelines, with a 0.5 to 1 cm planning target volume margin. A subset of patients received pelvic field radiation therapy and androgen deprivation therapy (ADT) per the institutional guidelines, which generally included patients with a higher Gleason score, younger age, or lymph node positivity.

The pelvic field was defined using a standard CTV margin of 7 mm to 8 mm around pelvic blood vessels with an additional 7 mm to 8 mm planning target volume expansion. Prior to 2007, image guidance consisted of alignment to bony anatomy but after 2007, cone beam computed tomography was used to evaluate soft-tissue alignment of the prostate bed. ADT consisted of dual-agent therapy with an antiandrogen and a luteinizing hormone-releasing hormone agonist. ADT was generally given for a duration of 4 months, beginning 2 months prior to radiation therapy.

Dose-volume histogram analysis

For normal-tissue DVH analysis, the rectum was contoured from the ischial tuberosities to the rectosigmoid junction. The bladder was defined by its outer wall. The trigone was retrospectively contoured on archived image sets as the posterior triangular portion of the bladder between the vesicoureteral junctions superiorly and the vesicourethral junction inferiorly. DVH parameters were analyzed in association with the maximal Common Toxicity Criteria (CTC) version 3.0 toxicity grade. DVH parameters for the rectum, bladder, trigone, and bladder excluding the clinical target volume (bladder-CTV) were evaluated for compliance with all guidelines from RTOG 0534 (rectum V65, 40 Gy ≤35, 55%, and bladder-CTV V65, 40 ≤50, 70%, respectively) and institutional guidelines (rectum V70, 65, 40 ≤20, 40, 80% and bladder V70, 65, 40 ≤30, 60, 80%, respectively; Table 1). The institutional dose constraints were initially proposed in 2007 to limit morbidity for men with intact
prostate cancer who received external beam radiation therapy.16

Follow up

Patients were seen 4 to 6 weeks after therapy and then every 6 months for the first 2 years. After 2 years, patients were seen every 6 to 9 months until 5 years after therapy, after which they were seen annually. Both GU and GI systems were evaluated at each follow-up visit. RTOG and CTC toxicity grades were recorded prospectively during follow up after 2007. Patients who completed treatment prior to 2007 were retrospectively assigned CTC toxicity grades. Toxicities were graded relative to baseline pre-radiation therapy function. Late toxicities were defined as those that occurred >3 months after radiation therapy. For the purposes of this study, only late CTC toxicity grades were analyzed.

Statistical analysis

Freedom from GI and GU toxicities was estimated using the Kaplan-Meier method. Follow-up time was calculated from the end of radiation therapy. Any single event that met the criteria for the toxicity grade that was analyzed would permanently drop the freedom-from-toxicity curve. Several clinical, disease, and treatment factors were tested against late GU and GI toxicities in the univariate analysis using the log-rank test. These factors included age, pelvic radiation therapy, radiation therapy dose, anticoagulation use, ADT, time from radical prostatectomy (RP) to radiation therapy, tobacco history, and whether RTOG and/or institutional guidelines were met. All statistical analysis was performed with JMP13 (SAS Institute, Cary, NC).

Results

Patient characteristics

A total of 164 men were identified as eligible for this study. Five patients were excluded due to no available toxicity data, which yielded a total of 159 analyzable cases. The median age was 61 years. The median pre-RP prostate-specific antigen level was 7. Most men had pT3N0 disease and Gleason score ≥7. Detailed patient characteristics are presented in Table 2.

Treatment parameters

The median time from RP to radiation therapy was 22 months, which was given as adjuvant (13%) or salvage (87%) therapy. The median dose to the prostate bed was 66.6 Gy (interquartile range [IQR], 66-68.4). Seventy-three men (46%) received both pelvic lymph node irradiation (median dose 50.4 Gy) and concurrent ADT (median duration 4 months).

Characterization of late toxicity

The median follow-up time was 33 months from the end of radiation therapy to the last follow up. Freedom from grade 2 or higher (G2+) GI and GU toxicity at 4 years were both 91%. G2 + GI (n = 12) and GU (n = 15) toxicity included 4% diarrhea (n = 6), 4% hemorrhage (n = 6), and 1% proctitis (n = 1), and 4% urinary frequency (n = 7), 1% obstructive (n = 2), 2% cystitis (n = 3), and 3% incontinence
Two patients had G3 + GU toxicity and no patients had G3 + GI toxicity.

Dose-volume histogram analysis and univariate analysis of factors that are associated with late toxicity

A total of 141 of 159 patients (89%) had complete DVH data available for analysis. A previously used treatment planning software was no longer accessible for the remaining patients. A total of 89 men had simulation image sets available in which the trigone could be contoured and the CTV could be subtracted from the bladder with dose recalculations. The median volume of bladder and bladder-CTV were 180 cc and 154 cc, respectively. The trigone median volume was 16.4 cc (IQR, 12.5-20.6 cc; Range, 6-35 cc).

RTOG 0534 rectum and bladder goals were not achieved in 65% and 41% of cases, respectively. If the bladder-CTV volume was greater than the median, RTOG bladder dose constraints were more likely to be met (66% vs. 49%; \( P = .09 \)). The institutional goals were not achieved in 21% of rectum and 25% of bladder cases, respectively. Neither the RTOG nor the institutional proposed goals were significantly associated with late toxicity (Fig 1A-D). The median bladder trigone V70 Gy was 23%. Dose to the bladder trigone was not associated with GU toxicity (Table 3). Dose to the bladder-CTV was not associated with GU toxicity at various dose levels (Table 4). The univariate analysis for age, pelvic radiation therapy, radiation therapy dose, anticoagulation use, ADT, time from RP to radiation therapy, and tobacco history were not associated with toxicity (Table 5).

Discussion

In this study, we describe the late toxicities of post-RP IMRT and investigated DVH-toxicity relationships. We found low rates of long-term morbidity with a 4-year freedom from...
G2 + toxicity of 91% in both the GI and GU domains. No tested DVH parameter threshold was significantly associated with late toxicity, although the analyses were likely underpowered due to the low event rate. Patient and treatment factors that were tested in this study were not associated with toxicity including age, anticoagulation use, ADT, time from RP to radiation therapy, tobacco history, and compliance with RTOG and/or institutional dose constraints.

Our report that >90% of men who received post-RP IMRT were free from G2 + GI and GU toxicity at 4 years contributes to the growing evidence that modern PPRT has a low risk of significant morbidity. Retrospective studies of post-RP IMRT have reported 2-year CTC late G2 + GI and GU toxicity rates of 0% to 2% and 12% to 17%, respectively.17-19 A recent prospective phase 2 study of 68 men who were treated with guideline-based post-RP IMRT reported cumulative 5-year CTC late G2 GI and GU toxicity incidences of 12.3% and 10.6%, respectively, with no G3 + toxicities.20 These and our results compare favorably with the RTOG late G2 + GU toxicity of 21.3% that was reported in European Organisation for Research and Treatment of Cancer study 22911 and the 23.8% complication rate that was reported in Southwest Oncology Group study 8794 (both studies used conventional radiation therapy techniques).27 Several studies also demonstrated no significant long-term changes in patient-reported quality of life after PPRT.21-23 Collectively, these findings should alleviate any concerns of long-term PPRT toxicity that may lead to underutilization.

To maximally exploit the advantages of IMRT, DVH-toxicity relationships of critical organs must be well defined. Normal-tissue complication probability modeling predicts that late G3 + GI and GU toxicities increase by 1.2% and 0.7%, respectively, per 1 Gy increase in prescription dose with an upward inflection point in the 68 Gy to 70 Gy range,24 which suggests that critical organ dose thresholds should exist. Indeed, a retrospective study of 128 men who received conventional or 3-dimensional conformal radiation therapy found that rectal V50 ≤63% and acute GI bleeding were independently predictive of late GI bleeding in the multivariate analysis.25 However, this rectal DVH constraint is more permissive than the RTOG goal of rectum V40 ≤55% and its relevance to post-RP IMRT remains unclear. In the prospective trial of guideline-based post-RP IMRT that reported low rates of late G2 toxicity, 97% of patients met planning constraints of rectal wall D1cc ≤66 Gy, posterior rectal wall D1cc ≤55 Gy, and bladder wall D2cc ≤67.3 Gy.20 However, both the rectum and bladder were contoured as hollow organs with 3 mm thick walls, which complicated comparisons to RTOG and other institutional guidelines.

To our knowledge, our analysis is the first to evaluate the association of RTOG PPRT DVH goals with late toxicity. The absence of significant associations between late G2 + toxicity and the assessed DVH constraints suggests that failing to satisfy RTOG normal-tissue sparing goals has

### Table 3
Four-year freedom from grade ≥2 genitourinary toxicity stratified by dose to trigone (n = 89)

| Genitourinary Toxicity | V70 Gy < 30 (vs. ≥30) | V70 Gy < 23% (median) | V70 Gy < 20% | V70 Gy < 15% | V70 Gy < 10% | V70 Gy < 5% |
|------------------------|-----------------------|-----------------------|--------------|--------------|--------------|--------------|
|                        | 91% vs. 89%, P = .49  | 93% vs. 87%, P = .17  | 93% vs. 88%, P = .24 | 92% vs. 89%, P = .35 | 92% vs. 90%, P = .46 | 91% vs. 90%, P = .58 |

### Table 4
Four-year freedom from grade ≥2 genitourinary toxicity stratified by dose to median volume of bladder-clinical target volume (n = 89)

| Genitourinary Toxicity | V70 Gy < 5% (vs. ≥5) | V65 Gy < 27% | V60 Gy < 37% | V50 Gy < 50% |
|------------------------|-----------------------|--------------|--------------|--------------|
|                        | 93% vs. 88%, P = .21  | 90% vs. 90%, P = .62 | 91% vs. 89%, P = .52 | 91% vs. 90%, P = .61 |

### Table 5
Freedom from grade ≥2 gastrointestinal and genitourinary toxicity stratified by clinical parameters

| Tobacco (history vs. never; n = 154) | Gastrointestinal | Genitourinary |
|---------------------------------------|------------------|---------------|
| .58                                   | .39              |
| Time from radical prostatectomy to radiation therapy >22 mo (median; yes vs. no; n = 158) | .20 | .99 |
| .99                                   | .36              |
| Age >60 years (median; yes vs. no; n = 158) | .28 | .77 |
| Radiation therapy dose >66 Gy (median; yes or no; n = 158) | .09 | .85 |
| Pelvic lymph node radiation therapy (yes vs. no; n = 158) | .48 | .39 |
| Androgen deprivation therapy use (yes vs. no; n = 158) | .89 | .48 |
| Prostate bed volume >91 cc (median; yes or no; n = 89) | .87 | .83 |
| Rectal volume >92 cc (median; yes vs. no; n = 140) | .47 | N/A |
| Bladder volume >180 cc (median; yes vs. no; n = 140) | N/A | .95 |

N/A, non-applicable.
limited long-term clinical consequences. Our results are consistent with a recent study that demonstrated no change in late toxicity after RTOG guideline adoption despite significant increases in prostate bed volumes and GU DVH parameters. Until stronger evidence of DVH-toxicity relationships is available from RTOG 0534 and other randomized trials, the adoption of dose constraints as established in the intact setting makes sense, which in our analyses was no less useful than RTOG 0534 guidelines. Although dose constraints in the relatively lower dose of the postoperative setting should conceptually be more conservative than those for the intact setting to achieve a biologically equivalent effect on normal tissues, maintaining consistent guidelines between the intact and postoperative settings is useful, particularly in the absence of any known discriminating metrics between both settings.

We did not observe a relationship between dose to the bladder or bladder trigone and late GU toxicity in the current study. However, previous data have demonstrated an association between bladder V70 and patient-reported urinary incontinence after PPRT. Furthermore, the bladder trigone has been proposed to play roles in both bladder filling and micturition, which suggests a plausible mechanism for urinary side effects from high-dose radiation-mediated disruption of trigone physiology. In a dosimetric study of IMRT for intact prostate cancer, the maximum dose to the trigone predicted large post-treatment increases in urinary symptoms and trigone V90 was associated with late G2 + GU toxicity. Therefore, further research to investigate the effects of minimizing trigone dose on late GU toxicity is warranted.

Prior studies have identified patient and treatment factors other than normal-tissue doses that modulate late toxicity risk. Specifically, older age and anticoagulation use have been associated with increased late GI toxicity, and tobacco use has been associated with increased late GU toxicity. Although adjuvant ADT has been reported to decrease rectal radiation tolerance, recent level 1 evidence revealed no increased late toxicity from 6 months of concurrent and adjuvant ADT compared with salvage post-RP radiation therapy alone. The association of radiation therapy timing after RP on urinary incontinence is controversial. Finally, although diabetes mellitus has been shown to increase the risk of late GU toxicity, data with regard to its impact on late GI toxicity are conflicting. Our analysis revealed no significant association of late GI or GU toxicity with age, anticoagulation use, tobacco history, ADT, or time from RP to radiation therapy. The absence of these associations may be attributed in part to the lower radiation doses that are prescribed in the post-RP setting.

This study bears the limitations of its retrospective design. RTOG toxicity grades were recorded prospectively for all patients but CTC grades were retrospectively assigned prior to 2007 and thus potentially biased in some cases. Although our cohort of 164 men is comparable with or larger than those in other published studies of post-RP IMRT, the low rates of late G2 + GI and GU toxicities suggest that much larger cohorts may be required to sufficiently evaluate DVH-toxicity relationships.

The narrow range of prescription doses (IQR, 66-68.4 Gy) represented in our cohort also limited our ability to investigate high-dose effects on normal tissues. Finally, the median follow-up time of 33 months may not have been sufficient to capture late GU toxicity, which—unlike GI toxicity—may increase even >2 years after radiation therapy. With a longer follow-up period, DVH-toxicity relationships in the GU domain may have become significant. Despite these limitations, our study provides useful clinical information to evaluate the risk of late toxicities from PPRT while we wait for the results of large prospective data studies such as RTOG 0534.

In our practice, we continue to prescribe 64 Gy for adjuvant PPRT and 68 Gy to 68.4 Gy for standard salvage PPRT while using absolute constraints (rectum V70, 65, 40 ≤20, 40, 80% and bladder V70, 65, 40 ≤30, 60, 80%, respectively) according to our institutional intact prostate cancer guidelines.

With advances in delivery such as volumetric modulated arc therapy, stricter constraints for intact prostate cancer (rectum V70, 65, 40 ≤10, 20, 40% and bladder V70, 65, 40 ≤15, 30, 60% respectively) are the initial planning goal and often achievable in the postoperative setting. In men with a gross local recurrence, we consider a simultaneous integrated boost to deliver ≥70 Gy to the recurrent disease but also evaluate the normal tissue V70 (particularly in the bladder trigone) to potentially reduce the risk of late GU toxicity.

Conclusions

Post-RP IMRT resulted in low rates of morbidity with >90% of men free from late G2 + toxicity in the GI and GU domains at 4 years. Neither RTOG 0534 nor institutional guidelines were significantly associated with late toxicity. In the absence of well-established DVH-toxicity relationships, the use of intact prostate-cancer normal-tissue sparing goals for post-RP IMRT is reasonable. Risk factors that increase late morbidity after dose-escalated radiation therapy for intact prostate cancer may not be relevant for men who receive lower adjuvant or salvage radiation doses.

References

1. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial. J Urol. 2009;181:956-962.
2. Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380:2018-2027.
3. Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the APRO 96-02/AUA AP 09/95 trial. *Eur Urol*. 2014;66:243-250.

4. Trott BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. *JAMA*. 2008;299:2760-2769.

5. Shipley W, Seiferheld W, Lukka H, et al. Report of NRG Oncology/ RTOG 9601, A phase 3 trial in prostate cancer: Anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) in patients following radical prostatectomy (RP) with PT2-3pN0 disease and an elevated PSA. *Int J Radiat Oncol Biol Phys*. 2016;94:3-6.

6. Zaraosky NG, Churilla TM, Egleston BL, et al. Causes of death among cancer patients. *Ann Oncol*. 2017;28:400-407.

7. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. *JAMA*. 2006;296:2329-2335.

8. Maurice MJ, Zhu H, Abuassaly R. Low use of immediate and delayed postoperative radiation for prostate cancer with adverse pathological features. *J Urol*. 2015;194:972-976.

9. Mahal BA, Hoffman KE, Efstathiou JA, Nguyen PL. National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009. *Clin Genitourin Cancer*. 2015;13:e167-e172.

10. Sineshaw HM, Gray PJ, Efstathiou JA, Jamal A. Declining use of radiotherapy for adverse features after radical prostatectomy: Results from the National Cancer Data Base. *Eur Urol*. 2015;68:768-774.

11. Marcus DM, Rossi PJ, Cooper S, Jani AB. Adoption of Radiation Therapy Oncology Group consensus guidelines for post-prostatectomy radiation therapy in an academic tertiary care center. *Radiat Oncol*. 2014;3:395-400.

12. Ghadjar P, Zieluzyk MJ, Pratt DE, et al. Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2014;88:339-344.

13. Zaraosky NG, Showalter TN, Ezzell GA, et al. ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. *Adv Radiat Oncol*. 2017;2:62-84.

14. Wiltshire KL, Brock KK, Haider MA, et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. *Int J Radiat Oncol Biol Phys*. 2007;69:1090-1099.

15. Gay HA, Barholt JD, O’Meara E, et al. Pelvic normal tissue contouring guidelines for radiotherapy: A Radiation Therapy Oncology Group consensus panel atlas. *Int J Radiat Oncol Biol Phys*. 2012;83:e353-e362.

16. Pederson AW, Fricono J, Correa D, et al. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: An exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. *Int J Radiat Oncol Biol Phys*. 2012;82:235-241.

17. Hunter GK, Brockway K, Reddy CA, et al. Late toxicity after intensity modulated and image guided radiation therapy for localized prostate cancer and post-prostatectomy patients. * Pract Radiat Oncol*. 2013;3:323-328.

18. Nath SK, Sandhu AP, Rose BS, et al. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2010;78:435-441.

19. Goenka A, Maguanco JM, Pei X, et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. *Eur Urol*. 2011;60:1142-1148.

20. Berline A, Cho E, Kong Y, et al. Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. *Pract Radiat Oncol*. 2015;5:e473-e482.

21. Meloteck JM, Liao C, Liu SL. Quality of life after post-prostatectomy intensity modulated radiation therapy: Pelvic nodal irradiation is not associated with worse bladder, bowel, or sexual outcomes. *PLoS ONE*. 2015;10:e0141639.22.

22. Son CH, Meloteck JM, Liao C, et al. Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. *Pract Radiat Oncol*. 2015;6:e179-e185.

23. Johnson ME, Zaorsky NG, Martin JM. Patient reported outcomes among treatment modalities for prostate cancer. *Can J Urol*. 2016;23:8535-8545.

24. Ohri N, Dicker AP, Trabulsi EJ, Showalter TN. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. *Eur J Cancer*. 2012;48:837-844.

25. Cozzarini C, Fiorino C, Ceresoli GL, et al. Significant correlation between rectal DTVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (6.6-6:70.2 Gy). *Int J Radiat Oncol Biol Phys*. 2003;55:688-694.

26. Ghadjar P, Hayoz S, Bernard J, et al. Acute toxicity and quality of life after dose-intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09/10. *J Clin Oncol*. 2015;33:4158-4166.

27. Parker C, Clarke N, Logue J, et al. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). *Clin Oncol (RC Coll Radiol).* 2007;19:167-171.

28. Roosen A, Sui G, Churilla TM, Liao C, et al. Causes of death among cancer patients. *Oncol*. 2017;94:3-6.

29. Marcus DM, Rossi PJ, Cooper S, Jani AB. Adoption of Radiation Therapy Oncology Group consensus guidelines for post-prostatectomy radiation therapy in an academic tertiary care center. *Radiat Oncol*. 2014;3:395-400.

30. Ghadjar P, Zieluzyk MJ, Pratt DE, et al. Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2014;88:339-344.

31. Zaorsky NG, Showalter TN, Ezzell GA, et al. ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. *Adv Radiat Oncol*. 2017;2:62-84.

32. Wiltshire KL, Brock KK, Haider MA, et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. *Int J Radiat Oncol Biol Phys*. 2007;69:1090-1099.

33. Gay HA, Barholt JD, O’Meara E, et al. Pelvic normal tissue contouring guidelines for radiotherapy: A Radiation Therapy Oncology Group consensus panel atlas. *Int J Radiat Oncol Biol Phys*. 2012;83:e353-e362.

34. Pederson AW, Fricono J, Correa D, et al. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: An exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. *Int J Radiat Oncol Biol Phys*. 2012;82:235-241.

35. Hunter GK, Brockway K, Reddy CA, et al. Late toxicity after intensity modulated and image guided radiation therapy for localized prostate cancer and post-prostatectomy patients. *Pract Radiat Oncol*. 2013;3:323-328.

36. Nath SK, Sandhu AP, Rose BS, et al. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2010;78:435-441.

37. Goenka A, Maguanco JM, Pei X, et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. *Eur Urol*. 2011;60:1142-1148.

38. Berline A, Cho E, Kong Y, et al. Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. *Pract Radiat Oncol*. 2015;5:e473-e482.